Trial Profile
Comparison of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Patients with Relapsing Remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2020
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Oct 2017 Results of patterns of regional gray matter and white matter atrophy (n=55) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
- 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.